Abstract 2887
Background
Hand-foot skin reaction (HFSR) is the most common and most serious adverse event induced by multikinase inhibitors (MKIs). About 9%–62% patients receiving sorafenib or sunitinib treatments develop HFSR. Severe HFSR leads to dose reduction or suspension of MKI treatment.
Methods
Twenty-seven HFSR patients induced by sorafenib or sunitinib were included. SAS statistical software was used and patients were randomly divided into 2 groupx: experimental group (14 cases) and control group (13 cases). Tong-Luo-San (TLS) was locally administered for 7 days (20 min, bid), compared with placebo as blank control. Observation parameters included pain numerical rating scale (NRS) scores, HFSR grading of National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE), clinical grading of National Comprehensive Cancer Network (NCCN) grade in Impact of Pain Measurement Scores, total effective rate, analgesic efficacy rate and adverse events.
Results
NRS scores, HFSR grade and NCCN grade in impact of pain measurement scores decreased obviously after 7 days' treatment in the experimental group (P
Conclusions
TLS significantly reduced HFSR grade, alleviated pain and improved patients' quality of life. It was also safe and convenient to use.
Clinical trial identification
Legal entity responsible for the study
China-Japan Friendship Hospital
Funding
Ministry of Science and Technology of People's Republic of China
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract